

## **H.C. WAINWRIGHT STRENGTHENS ITS BIOTECHNOLOGY EQUITY RESEARCH FRANCHISE WITH THE ADDITION OF DEBJIT CHATTOPADHYAY**

NEW YORK, November 7 , 2017 - H.C. Wainwright & Co., LLC ("HCW"), announced today that Debjit Chattopadhyay, Ph.D., has joined the firm as a Managing Director in Biotechnology Equity Research. Dr. Chattopadhyay will focus his coverage on companies in the gene therapy and rare diseases space, among others.

Dr. Chattopadhyay has over 12 years of experience as a Senior Biotechnology Analyst, most recently at Janney Montgomery Scott and Roth Capital Partners. Earlier in his career, Dr. Chattopadhyay worked as a consultant to biopharmaceutical companies. He received his Ph.D. from the University of Connecticut and served as an oncology research fellow at Memorial Sloan Kettering Cancer Center.

HCW's Chief Executive Officer, Mark Viklund, commented, "We are excited that Debjit has joined the Biotechnology Research team at HCW. His expertise in evaluating and identifying breakthrough technologies and assisting in the development of commercialization strategies will be invaluable to HCW in providing high quality advice to both its corporate and investor client base."

### **About H.C. Wainwright & Co., LLC**

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the CMPO (Confidentially Marketed Public Offering), PIPE (private investment in public equity) and RD (registered direct offering) transaction markets according to Informa Business Intelligence Inc. H.C. Wainwright was established in 1868 and is headquartered in New York City.